DE69935331D1 - Verfahren und verbindungen zur behandlung der depression - Google Patents
Verfahren und verbindungen zur behandlung der depressionInfo
- Publication number
- DE69935331D1 DE69935331D1 DE69935331T DE69935331T DE69935331D1 DE 69935331 D1 DE69935331 D1 DE 69935331D1 DE 69935331 T DE69935331 T DE 69935331T DE 69935331 T DE69935331 T DE 69935331T DE 69935331 D1 DE69935331 D1 DE 69935331D1
- Authority
- DE
- Germany
- Prior art keywords
- compounds
- disorders
- depression
- active
- treating depression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
- C07C217/10—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9254698P | 1998-07-13 | 1998-07-13 | |
US92546P | 1998-07-13 | ||
PCT/US1999/015857 WO2000002551A2 (en) | 1998-07-13 | 1999-07-12 | Methods and compounds for treating depression |
Publications (2)
Publication Number | Publication Date |
---|---|
DE69935331D1 true DE69935331D1 (de) | 2007-04-12 |
DE69935331T2 DE69935331T2 (de) | 2007-10-31 |
Family
ID=22233751
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69935331T Expired - Fee Related DE69935331T2 (de) | 1998-07-13 | 1999-07-12 | Verfahren und verbindungen zur behandlung der depression |
Country Status (8)
Country | Link |
---|---|
US (1) | US20040039014A1 (de) |
EP (1) | EP1096926B1 (de) |
AT (1) | ATE355054T1 (de) |
AU (1) | AU771252B2 (de) |
CA (1) | CA2336962A1 (de) |
DE (1) | DE69935331T2 (de) |
ES (1) | ES2283122T3 (de) |
WO (1) | WO2000002551A2 (de) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR021155A1 (es) | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
US6433196B1 (en) * | 2000-02-17 | 2002-08-13 | Sumika Fine Chemicals Co., Ltd. | Production method of citalopram, intermediate therefor and production method of the intermediate |
EP1587781A1 (de) * | 2002-11-05 | 2005-10-26 | Eli Lilly And Company | 3-aryloxy/thio-2,3-substituierte propanamine und deren verwendung zur inhibierung der wiederaufnahme von serotonin und norepinephrin |
WO2004043904A1 (en) | 2002-11-05 | 2004-05-27 | Eli Lilly And Company | 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake |
WO2005000216A2 (en) * | 2003-05-27 | 2005-01-06 | Forest Laboratories, Inc. | Combination of an nmda receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders |
US7517899B2 (en) | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
US7414052B2 (en) | 2004-03-30 | 2008-08-19 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
ES2340180T3 (es) | 2004-06-01 | 2010-05-31 | F.Hoffmann-La Roche Ag | 3-amino-1-arilpropil-indoles como inhibidores de reabsorcion de monoaminas. |
WO2007061868A2 (en) * | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
CN101316818B (zh) | 2005-11-30 | 2011-08-31 | 弗·哈夫曼-拉罗切有限公司 | 3-氨基-1-芳基丙基吲哚类和氮杂取代的吲哚类 |
JP2009523705A (ja) | 2005-11-30 | 2009-06-25 | エフ.ホフマン−ラ ロシュ アーゲー | 3−アミノ−1−アリールプロピルインドールの合成方法 |
BRPI0619184A2 (pt) | 2005-11-30 | 2011-09-13 | Hoffmann La Roche | 3-amino-2-arilpropil azaindóis e usos destes |
US20080081067A1 (en) * | 2006-10-03 | 2008-04-03 | Gupta Manishkumar | Sustained release pharmaceutical compositions of venlafaxine and process for preparation thereof |
US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US8461389B2 (en) | 2008-04-18 | 2013-06-11 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
US8546576B2 (en) * | 2008-06-06 | 2013-10-01 | Sk Biopharmaceuticals Co., Ltd. | 3 or 4-substituted piperidine compounds |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2077916A1 (en) * | 1970-02-24 | 1971-11-05 | Dainippon Pharmaceutical Co | Amino-alkanols as antidepressants |
GB1443441A (en) * | 1973-02-24 | 1976-07-21 | Beecham Group Ltd | Pharmaceutical compositions comprising diphenylpropanolamine deri vatives |
EP0028682A3 (de) * | 1977-07-04 | 1981-08-05 | Astra Läkemedel Aktiebolag | Bei der Herstellung von Verbindungen mit antidepressiver oder tranquillisierender Wirkung nützliche Zwischenprodukte |
EP0450689A1 (de) * | 1990-04-02 | 1991-10-09 | Akzo Nobel N.V. | Isochromanderivate |
FR2664594B1 (fr) * | 1990-07-11 | 1992-09-18 | Adir | Polymethylene-imines disubstituees, leur procede de preparation et les compositions pharmaceutiques les contenant. |
US6071970A (en) * | 1993-02-08 | 2000-06-06 | Nps Pharmaceuticals, Inc. | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
US6087346A (en) * | 1993-06-23 | 2000-07-11 | Cambridge Neuroscience, Inc. | Sigma receptor ligands and the use thereof |
EP1123922B1 (de) * | 1994-02-08 | 2006-11-29 | Nps Pharmaceuticals, Inc. | An einer neuen Stelle von Rezeptorabhängigen Kalziumkanälen wirkende Verbindungen zur Behandlung von neurologischen Erkrankungen |
EP0912494A1 (de) * | 1996-06-07 | 1999-05-06 | Nps Pharmaceuticals, Inc. | An einer neuen stelle von rezeptorabhängigen kalziumkanälen wirkende verbindungen zur behandlung von neurologischen erkrankungen |
-
1999
- 1999-07-12 WO PCT/US1999/015857 patent/WO2000002551A2/en active IP Right Grant
- 1999-07-12 DE DE69935331T patent/DE69935331T2/de not_active Expired - Fee Related
- 1999-07-12 EP EP99933987A patent/EP1096926B1/de not_active Expired - Lifetime
- 1999-07-12 ES ES99933987T patent/ES2283122T3/es not_active Expired - Lifetime
- 1999-07-12 CA CA002336962A patent/CA2336962A1/en not_active Abandoned
- 1999-07-12 AT AT99933987T patent/ATE355054T1/de not_active IP Right Cessation
- 1999-07-12 AU AU49919/99A patent/AU771252B2/en not_active Ceased
-
2001
- 2001-11-21 US US09/990,405 patent/US20040039014A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AU4991999A (en) | 2000-02-01 |
CA2336962A1 (en) | 2000-01-20 |
ES2283122T3 (es) | 2007-10-16 |
WO2000002551A2 (en) | 2000-01-20 |
DE69935331T2 (de) | 2007-10-31 |
US20040039014A1 (en) | 2004-02-26 |
AU771252B2 (en) | 2004-03-18 |
WO2000002551A3 (en) | 2000-09-21 |
EP1096926B1 (de) | 2007-02-28 |
ATE355054T1 (de) | 2006-03-15 |
EP1096926A2 (de) | 2001-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69935331D1 (de) | Verfahren und verbindungen zur behandlung der depression | |
DE60022050T2 (de) | Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems | |
NO20042964L (no) | Spiroazasykliske forbindelser som monoaminreseptormodulatorer | |
MY133238A (en) | Monoamine reuptake inhibitors for treatment for cns disorders | |
MY129189A (en) | Prostaglandin agonists and their use to treat bone disorders | |
BR0010061A (pt) | Tratamento de fibrose por antagonista de il-13 e cadeias de receptor il-13 | |
DE60122767D1 (de) | Indoly-lsulphonyl-verbindungen zur behandlung von störungen des zns | |
ATE431141T1 (de) | Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit | |
DK0751939T3 (da) | Naphthylamider som centralnervesystemmidler | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
WO2002000623A3 (en) | Aryl fused substituted 4-oxy-pyridines | |
NO20061575L (no) | Fremgangsmate for fremstilling av renzapride og mellomprodukter derav | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
DE60040878D1 (de) | Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen | |
HUP0202534A2 (hu) | Kondenzált pirrolkarboxamidok és a vegyületeket tartalmazó gyógyászati készítmények | |
ATE255094T1 (de) | Piperazinderivate zur behandlung der niedrigen harnwege | |
ATE290857T1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
DE60327335D1 (de) | Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson | |
DE69731657D1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
DE69905489T2 (de) | Protein c zur behandlung von sichelzellanämie und thalassämie | |
DE60121978D1 (de) | 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN | |
FR2809725B1 (fr) | Propanolaminotetralines, leur preparation et compositions pharmaceutiques en contenant | |
HUP0101057A2 (hu) | D1/D5 antagonisták alkalmazása rögeszmés kényszerképzetes zavarok, szomatoform zavarok, tudathasadásos étkezési zavarok, impulzív viselkedési zavarok és autizmus kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE288756T1 (de) | Verwendung von nk-1 rezeptorantagonisten zur behandlung von schweren depressionen, die von angstzuständen begleitet werden | |
ATE286390T1 (de) | Felabamat-derivate zur behandlung von neuropathischem schmerz |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |